SYBX Synlogic, Inc.: Price-to-Projected Revenue Ratio

Synlogic - graphic logo of issuer SYBX

Synlogic, Inc. (SYBX) is vulnerable to disruptions in global laboratory equipment supplies. The team maintains its position through the uniqueness of its "living" medicines platform, while the financial strategy relies on cost optimization and licensing. The forward price-to-sales ratio helps assess the business's market value relative to expected sales, with the latest reading standing at 1313.80.

Synlogic Inc. - SYBX Market Cap to Expected Sales Ratio (period 07/04/2022 - 05/10/2025)

Summary analytical data breakdowns for synlogictx.com (SYBX)

- market price and analyst price targets:
- company stock capitalization data:
Comprehensive company analysis:Synlogic Corp (SYBX)
Original product of Synlogic

The forward P/S reflects the market value of Synlogic, Inc. (SYBX) relative to its expected annual revenue, allowing for an assessment of the premium paid for future cash flow. By analyzing the forward P/S trend, an investor determines whether the capitalization is appropriate amidst the restructuring of Synlogic, Inc. (SYBX), where supply chain optimization and the change of laboratory partners directly impact the potential for preserving scientific assets.

Competitor analysis

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Price-to-Projected Revenue Ratio Amicus Therapeutics FOLD|Market Cap to Expected Sales Ratio 89bio.com (ETNB)|AGIO: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Structure Therapeutics Inc|MiMedx Group (MDXG) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue RZLT|Price-to-Projected Revenue Ratio Lexicon Pharmaceuticals|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune (ALT)|AARD - Market Cap to Future Revenue Ratio|Forward P/S Multiple SGMT (Sagimet)|Projected Price to Revenue BioAge Labs, Inc|Biomea Fusion, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Quince Therapeutics QNCX|GUTS: Forward P/S Multiple|Forward Price-to-Revenue Multiple vTv Therapeutics|Forward Price-to-Revenue Multiple ATPC|PLUR: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio matinasbiopharma.com|Price-to-Projected Revenue Ratio Spruce Biosciences, Inc. SPRB|GLTO: Market Cap to Projected Revenue|Carmell Corp - Forward P/S Multiple|Lumos Therapeutics (LUMO) - Forward Price-to-Revenue Multiple|ONVO (Organovo Holdings, Inc.) - Forward Price-to-Revenue Multiple|RDUS - Market Cap to Expected Sales Ratio